The two key examples discussed above include prostate adenocarcinoma and EGFR mutant non-small cell lung cancer, two diseases where standard of care involves highly effective therapies targeting androgen receptor or EGFR signaling, respectively. The gene discussed is EGFR; the disease is prostate adenocarcinoma.